Various alphabetized medical records
Industries

Life Sciences Commercial Disputes

New product introductions in the life sciences sector are frequently complex, costly, and time-consuming undertakings, and collaborations between companies are common. Disputes may arise at all stages of development and commercialization. Our expertise helps clients navigate litigated and arbitrated disputes involving drug development and commercialization and analyze relevant commercial factors (size of the opportunity, therapeutic area, business risks, etc.). CRA has provided expert reports and testimony evaluating development and commercialization efforts and assessing damages associated with alleged contractual breaches and other commercial issues.

Our focus areas

Engagements

  • 01
    AAA dispute involving the breach of a contract between biopharmaceutical companies engaged in the development of monoclonal antibody therapeutics
    In an American Arbitration Association (AAA) dispute over early-stage drug candidates in a development agreement between two biopharmaceutical companies, CRA...
    View engagement
  • 02
    Milestone payments in funding agreement for a cystic fibrosis therapy
    CRA was retained by a non-profit organization to provide an expert opinion on damages in a breach of contract arbitration concerning a funding agreement...
    View engagement
  • 03
    Impact of channel stuffing of an antiviral product
    In a Canadian dispute for an antiviral product, CRA was retained to evaluate lost unit sales and lost profits suffered by a branded company from the allegedly...
    View engagement

Subscribe to recieve our latest Insights.

Subscribe